Array Biopharma (ARRY, Financial) experienced a significant stock drop, declining by 5.03% to $5.67 per share. The trading volume reached 3.94 million shares with a turnover rate of 2.59% and a price fluctuation of 6.31%. Recent financial reports show revenue of $231 million, a net loss of $141 million, and earnings per share of -$1.02. The company has a gross profit of $69.44 million and a price-to-earnings ratio of -5.79. Among 24 rating institutions, 58% recommend buying, 38% suggest holding, and 4% advise selling.
In the solar industry, Array Biopharma's sector saw a 1.12% decline. Array Technologies Inc, a manufacturer of ground-mounted systems for solar projects, operates mainly in the U.S., Australia, Spain, Brazil, and other regions.
